TRUFFLE-CAPITAL
26.6.2020 09:12:07 CEST | Business Wire | Press release
On the face of it, the "Truffle 100" 2020 has drawn the curtain on a decade of continuous growth, which has been abruptly halted by the Covid-19 pandemic:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005086/en/
- Several records were set in 2019: cumulative turnover for the sector was €10.8bn, total workforce in the sector stood at 157,000 jobs including 25,000 in R&D. Profitability at 11.1 % is very close to its historical high of 2006-2007. Moreover, buybacks and stock market transactions were sharply higher.
Despite the fact that the solid foundations built over the last decade will be exposed to a brutal shock in 2020, the Truffle 100 clearly shows that the areas in which software publishers have invested the most extensively are those that will be the most vital to withstand the current crisis and support the economic recovery:
- Thanks to their profit margins, which have returned to previous levels, software publishers have been able to ensure continuous research in crucial areas (in particular, the Cloud and artificial intelligence, which are the two major market trends) to support the transition to teleworking in the economy of tomorrow.
While 62% of software publishers forecast a downturn in 2020, 94% expect a return to growth in 2021.
Commenting on the 15th edition of the "Truffle 100", Bernard-Louis Roques, General Manager and Co-founder of Truffle, declared: "Software is a digital business and software publishers have been among the quickest to adapt to the crisis. In just a few months, Covid-19 brought about a forced acceleration in terms of the company's digital transition, with an irreversible digitalization of uses and organizations. Publishers will play a vital role in the development of the "post-Covid world". Finally, I would like to thank Cédric Ô, the French Secretary of State for the Digital Economy, for agreeing to sponsor the 15th edition of the "Truffle 100", which is more than a just an overview of the past, it is a leading indicator of the future. "
Xavier Negiar, Chairman of the consulting and analysis firm teknowlogy Group which carried out the study and analysis, added:
"As grey as this picture may be, there has been a major trend in this software market to prepare for the end of the crisis. Now is the time to develop programs that are capable of reviving the market. And to achieve this, surely the best approach is to help companies find their own way out of this crisis. "
Cédric Ô, the French Secretary of State for the Digital Economy concluded:
"Software publishers are at the core of all these changes taking place in our societies. They act as stakeholders as well as sentinels and open up new pathways for improvement for the companies they support, the employees who use their solutions and for each and every citizen, which result in significant transformations to life and work. It is this key role that explains the economic strength and resilience of this strategic sector, which is central to France's entrepreneurial fabric and excellence.
The 15th edition of the "Truffle 100", as well as the previous editions, can be viewed on the following website: https://www.truffle100.fr/
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (BioTech and MedTech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Since its creation, Truffle Capital has raised nearly €1.1 billion and has supported over 70 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds.
About teknowlogy Group
For more than 45 years, PAC and CXP have been providing visionary and meticulous support, helping stakeholders to grow and adapt in what has become today's IT ecosystem, as well as assisting companies seeking to accelerate their digitalization process. PAC's M&A teams serve the investment fund community both with regard to acquisitions and in the analysis of the coherence of the BP (Business Plan) of their holdings in view of market trends. PAC's teams of analysts also advise ESNs, software publishers and IT service providers in terms of deciphering technological needs to enable them to adapt their strategy to offer solutions and services, owing to their oversight of European and international markets. Thanks to SITSI®, its international platform for real-time monitoring, PAC maintains an up-to-date vision of technologies and markets, and provides its customers with strategic analyses and solution benchmarks for a 360° outlook of the IT market. CXP's Project Consulting teams support TIEs and SMEs in drafting specifications, identifying IT service providers, selecting and implementing solutions adapted to their digital transformation challenges. Thanks to the MyTeknow site - CXP's platform - users now have access to a real-time monitoring of the IT services on offer in France to TIEs and SMEs.
More information: www.truffle.com — Twitter: @trufflecapital
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
